Intelligence for the Decisions that Matter Most

Pathology's AI platform1 for the experts answering medicine's biggest questions, from discovery through diagnosis.

Clinical LAB SOLUTIONS

At the point of review

An immersive, operationally intelligent review experience for pathology's experts.

CLINICAL
Life Sciences SOLUTIONS

From tissue to treatment

Turn tissue into biomarker insights, move therapies through development and get them to the patients who need them.

LIFE SCIENCES

Trusted by 16 of the top 20 pharma companies and over 4,000 hospitals and clinics globally.

Bayer logo with green and blue circular swooshes around the name Bayer in dark letters.
Cleveland Clinic logo with a blue and green square emblem and text.
Unilabs logo with stylized star made of orange and red shapes and red text.
Labcorp logo with blue concentric circles on the left and black text on the right.
Red cursive text spelling Lilly against a transparent background.
Bristol Myers Squibb company logo with purple vertical bar design and bold text.
PathGroup logo with green and black text and slogan Physician Centered. Patient Focused.
Daiichi-Sankyo brand name with a circular blue and green gradient logo
Bayer logo with green and blue circular swooshes around the name Bayer in dark letters.
Cleveland Clinic logo with a blue and green square emblem and text.
Unilabs logo with stylized star made of orange and red shapes and red text.
Labcorp logo with blue concentric circles on the left and black text on the right.
Red cursive text spelling Lilly against a transparent background.
Bristol Myers Squibb company logo with purple vertical bar design and bold text.
PathGroup logo with green and black text and slogan Physician Centered. Patient Focused.
Daiichi-Sankyo brand name with a circular blue and green gradient logo
CONCENTRIQ

Pathology AI for
Precision Medicine

The Concentriq¹ portfolio powers precision medicine from discovery through diagnosis, with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review.

EXPLORE CONCENTRIQ

Best in KLAS 2026

Concentriq is the highest-rated digital pathology platform in both the United States and Europe. Find out why we’re rated #1 by customers.

Best in KLAS 2026 award badge for Digital Pathology in Europe with an arch illustration.
READ THE KLAS REPORT

Trusted at scale. Proven in practice.

12M

cases managed annually by Proscia's customers

4,000+

hospitals and clinics served worldwide

16 of 20

top pharmaceutical companies run on Concentriq

30,000+

studies powered by Concentriq, from discovery to trials

100%

of customers told KLAS they would buy Concentriq again

FEATS OF STRENGTH VIDEO SERIES

The hardest part of going digital isn't the technology.

Behind every successful digital pathology deployment is a pathologist or lab leader who broke down barriers and moved their organization to Pathology AI. Feats of Strength tells their stories.

SEE THEIR STORIES

"The only way to evolve, to make our discipline evolve, is go for more."

Dr. Luis Cano
Clinical AI & Digital Pathology Consultant

"Understanding the needs from all of those groups of people, their various perspectives, packaging them into a justification that made sense for everybody and showed value to the entire organization, those were some of the most critical steps that we undertook."

Dr. Cherub Kim
Director, Medical Affairs and Clinical Informatics Lead

“Just go ahead and start. It’ll give you something to grow on.”

Dr. Amanda Hemmerich
Global Director of Digital Pathology Innovation
IQVIA Laboratories

"I think the defining moment for me was when I saw that first scanner and saw what it could do. It was like, okay, someday, this is the way we're gonna work.”

Dr. Derrick Forchetti
Pathologist
South Bend Medical Foundation

Latest Resources

Blog

Freedom to Grow: Why an Open, Interoperable Platform Is Non-Negotiable for Digital Pathology

As laboratories scale digital pathology, interoperability gives them the freedom to add sites, connect systems, adopt new AI applications, and pursue growth without rebuilding their workflows. Ashley Faber explores why true openness must extend beyond a vendor’s claims and how Concentriq supports flexibility through integrations designed around pathologists’ day-to-day work, a commitment to DICOM, a broad precision medicine AI portfolio, and the Predetermined Change Control Plan authorized in Proscia’s latest FDA clearance for Concentriq AP-Dx.
Read more
Press Release

Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan

Proscia® has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Concentriq® AP-Dx. The clearance includes compatibility with the Leica Aperio® GT 450 DX slide scanner, cloud deployment, and a Predetermined Change Control Plan (PCCP). Concentriq AP-Dx is a digital pathology platform for primary diagnosis used by laboratories of all sizes. 
Read more
Webinar

Meet the Next Generation of Concentriq: Pathology’s AI Platform for Precision Medicine

Diagnostic labs and drug development programs are under more pressure than ever — and a pathology platform with AI bolted on can't keep up. See the first official demo of Concentriq Fifth Generation, built with an enterprise AI layer at its core. Hear directly from customers optimizing clinical diagnostic workflows and advancing drug development research.
Save my spot
View all

¹ The Concentriq portfolio includes distinct configurations. Concentriq AP-Dx is cleared for primary clinical diagnosis. Concentriq AP and Concentriq LS are for Research Use Only; not for use in diagnostic procedures. Proscia’s interoperable AI applications and native AI features are available for research use only on Concentriq AP. In some geographies, certain AI applications may be interoperable with Concentriq AP-Dx. Contact the AI application manufacturers for regulatory authorization status and indications for use. Proscia’s native AI features in Concentriq AP-Dx do not meet the definition of Artificial Intelligence as defined by Regulation (EU) 2024/1689.

Heading